

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF INDIANA**

SANDRA HUNTER, Individually and On  
Behalf of All Others Similarly Situated,

Plaintiff,

v.

ELANCO ANIMAL HEALTH  
INCORPORATED, JEFFREY N.  
SIMMONS, and TODD S. YOUNG,

Defendants.

Case No. 1:20-cv-01460-SEB-DML

**FIRST AMENDED CLASS ACTION  
COMPLAINT FOR VIOLATIONS OF  
THE FEDERAL SECURITIES LAWS**

**JURY TRIAL DEMANDED**

**TABLE OF CONTENTS**

I. NATURE OF THE ACTION AND OVERVIEW ..... 1

II. JURISDICTION AND VENUE ..... 5

III. PARTIES ..... 6

A. Plaintiffs ..... 6

B. Corporate Defendant ..... 6

C. Individual Defendants ..... 7

D. Securities Act Defendants ..... 8

IV. CONFIDENTIAL WITNESS (“CW”) FOUNDATION ALLEGATIONS ..... 10

V. SUBSTANTIVE ALLEGATIONS ..... 12

A. Background of Elanco’s Business: Its Products, Distributors, and the Aratana Merger ..... 12

B. Elanco’s Shifting Strategies to First “Clean Up” Its Inventory Channels and then Boost the Appearance of Sales and Growth Prior to the IPO ..... 16

C. Elanco Continued to Rely On Concealed Channel Stuffing to Show Growth During the Class Period, Obscuring the Risks Posed By Increasing Channel Inventory ..... 18

D. Further Undisclosed Distributor Changes and Channel Stuffing in 4Q 2019 Pose Additional Concealed Risks To Elanco’s Operations and Results ..... 21

E. Subtle Changes to Elanco’s SEC Filings in 3Q 2019 Suggest that Defendants Understood—But Did Not Disclose to the Market—the Risks of Increasing Channel Inventory and Elanco’s 4Q 2019 Distributor Changes ..... 23

F. The Undisclosed Risks Materialize With Disappointing First Quarter 2020 Results Announced on May 7, 2020 ..... 25

G. After the Class Period, Defendants’ Concealed and Misleading Channel Stuffing Is Exposed and Defendants Announce Further “Channel Inventory Reduction” for 2Q 2020 ..... 27

VI. DEFENDANTS’ VIOLATIONS OF THE EXCHANGE ACT ..... 29

A.	Defendants’ Materially False and Misleading Statements and Omissions In Violation of the Exchange Act.....	29
1.	The IPO Registration Statement .....	29
2.	3Q 2018 Financial Results and Earnings Call .....	34
3.	2019 Financial Guidance .....	39
4.	4Q and Full Year 2018 Financial Results and Earnings Call .....	42
5.	1Q 2019 Financial Results and Earnings Call .....	49
6.	Aratana Merger Registration Statement.....	55
7.	2Q 2019 Financial Results and Earnings Call .....	60
8.	September 11, 2019 Morgan Stanley Global Healthcare Conference .....	67
9.	3Q 2019 Financial Results and Earnings Call .....	67
10.	2020 Financial Guidance .....	76
11.	January 14, 2020 JP Morgan Healthcare Conference.....	80
12.	4Q and Full Year 2019 Financial Results and Earnings Call .....	81
13.	Defendants’ Statement on COVID-19 .....	87
B.	Additional Allegations Regarding Defendants’ Scienter.....	89
1.	Individual Defendants’ Knowledge of and Access to Information .....	89
2.	Corporate Scienter and <i>Respondeat Superior</i> .....	93
3.	Executive Bonus Payments Based on Inflated Performance .....	93
C.	Loss Causation.....	97
D.	Applicability of the Presumption of Reliance (Fraud-on-the-Market Doctrine) ..	99
VII.	VIOLETIONS OF THE SECURITIES ACT.....	101
VIII.	CLASS ACTION ALLEGATIONS .....	104
IX.	NO SAFE HARBOR .....	105

X. CLAIMS FOR RELIEF ..... 106

XI. PRAYER FOR RELIEF ..... 113

Lead Plaintiff Sandra Hunter and plaintiff Marla Strappe (“Plaintiffs”), individually and on behalf of all others similarly situated, by and through their attorneys, allege the following upon information and belief, except as to those allegations concerning Plaintiffs, which are alleged upon personal knowledge. Plaintiffs’ information and belief is based upon, among other things, their counsel’s investigation, which includes without limitation: (a) review and analysis of regulatory filings made by Elanco Animal Health Incorporated (“Elanco” or the “Company”) with the United States (“U.S.”) Securities and Exchange Commission (“SEC”); (b) review and analysis of press releases and media reports issued by and disseminated by Elanco; (c) interviews of former Elanco employees and other witnesses; (d) review of reports issued by industry and securities analysts; and (e) review of other publicly available information concerning Elanco.

## **I. NATURE OF THE ACTION AND OVERVIEW**

1. This is a class action on behalf of persons and entities that purchased or otherwise acquired Elanco securities between September 20, 2018 and May 6, 2020, inclusive (the “Class Period”), including persons or entities that acquired Elanco common stock pursuant to the Company’s merger with Aratana Therapeutics (“Aratana”) on or about July 18, 2019 (the “Aratana Merger”), and were damaged thereby. Plaintiffs pursue claims under the Securities Act of 1933 (the “Securities Act”) and Securities Exchange Act of 1934 (the “Exchange Act”).

2. Elanco was formed as a public company in a spin-off from Eli Lilly and Company (“Eli Lilly”) in September 2018 (the “IPO”). Elanco’s initial Form S-1 registration statement was filed with the SEC on August 2, 2018 (as amended on August 28, 2018 and September 6, 2018), and its final Form 424(b)(4) prospectus, incorporated by reference into the registration statement, was dated September 19, 2018 (collectively, the “IPO Registration Statement”). The IPO Registration Statement was declared effective on September 19, 2018 and Elanco shares began trading on September 20, 2018. The IPO offered 62.9 million shares of common stock priced at \$24 per share, and the net proceeds to Elanco were approximately \$1.7 billion.

3. Elanco develops, manufactures, and markets health products for companion and food animals. Its four primary product categories are: Companion Animal Disease Prevention

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.